|New from NCI|
|How Imatinib Transformed Leukemia Treatment and Cancer Research|
| ||Learn about the NCI-supported discoveries that led to the development of imatinib (Gleevec). These discoveries helped establish a new group of drugs known as targeted therapy that has changed the treatment of cancer.|
|Video—Introduction to Adolescent and Young Adult Cancers|
| ||This video covers basic facts about cancer in adolescents and young adults and discusses the unique challenges these patients face. |
|Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers|
Scientists have struggled to come up with a simple test to detect endometrial and ovarian cancers early, when they are most likely to respond to treatment. Can a liquid biopsy test called PapSEEK change that?
|Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer|
| ||Results from a large clinical trial testing a combination of the immunotherapy pembrolizumab (Keytruda) and chemotherapy in patients newly diagnosed with metastatic lung cancer may change clinical practice.|
|Does Muscle Mass Affect Cancer Survival?|
Read about a recent study in which researchers measured muscle mass in women with breast cancer and tracked its connection to survival.
|New Option for Women with Recurrent Ovarian Cancer|
The Food and Drug Administration (FDA) recently approved a new PARP inhibitor for women with ovarian cancer who meet certain criteria. Learn about PARP inhibitors and why they are helpful in treating this disease.
|PDQ Summary Updates|
|Non-Small Cell Lung Cancer Treatment |
We’ve revised our PDQ summary on non-small cell lung cancer (NSCLC) with updates to the tests used to diagnose and stage the disease and to the treatments used for different stages.
|Drug Information Updates|
|Ipilimumab Approved for Kidney Cancer|
We’ve updated our drug information summary with a recent FDA approval. Ipilimumab (Yervoy) is now approved to be used with nivolumab to treat renal cell carcinoma, which is a type of kidney cancer.
|Nivolumab Combination in Kidney Cancer|
Our updated drug information summary on nivolumab (Opdivo) includes the FDA’s recent approval of the drug for use with ipilimumab as a first-line therapy for renal cell carcinoma.
|Osimertinib Use in Lung Cancer|
We’ve updated our drug information summary to include FDA’s expanded approval for osimertinib (Tagrisso) in NSCLC. The drug is now approved as a first-line treatment in certain patients with metastatic NSCLC.
|Tocilizumab for Cytokine Release Syndrome|
We've added a new drug summary for tocilizumab (Actemra), which was approved by FDA to treat cytokine release syndrome (CRS) caused by CAR T-cell therapy. CRS is a severe side effect that can occur with some types of immunotherapy.
No hay comentarios:
Publicar un comentario